about
Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohortHyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome.Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes.Alternative complement pathway assessment in patients with atypical HUS.[Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.Genetics of hemolytic uremic syndromes.Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome.Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions.Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS).Anti-factor H autoantibodies assay.Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.C1q and its growing family.Heme interacts with c1q and inhibits the classical complement pathway.Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis.Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes.Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chainsAntibody polyreactivity in health and disease: statu variabilis.Heme: Modulator of Plasma Systems in Hemolytic Diseases.Mechanism and functional implications of the heme-induced binding promiscuity of IgE.Endothelial cells: source, barrier, and target of defensive mediators.Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.Mutational analyses of the recombinant globular regions of human C1q A, B, and C chains suggest an essential role for arginine and histidine residues in the C1q-IgG interaction.Functional and structural insight into properdin control of complement alternative pathway amplification.Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival.Loss of DGKε induces endothelial cell activation and death independently of complement activation.The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status.Functional complement C1q abnormality leads to impaired immune complexes and apoptotic cell clearance.A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody.Interaction of the globular domain of human C1q with Salmonella typhimurium lipopolysaccharide.Complement C1q-target proteins recognition is inhibited by electric moment effectors.C3dg-CR3 interaction in erythrophagocytosis.Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling.
P50
Q28741729-05921650-AB15-4EE2-8987-BADF82E8143AQ33385299-507418DE-FAA8-4F8B-93BA-8E63B1B89543Q33388474-B1C21F8C-F318-40F3-A44F-79A98B69406CQ33392010-DB7FD4F7-5309-48AD-8253-906C6C123E1CQ33393565-686B026E-09FD-4CE7-B0A9-C839F4084228Q33394393-AF6DFCE4-A001-4B4D-8E69-EA5E6D056BD5Q33399198-4AE67601-41F2-46D3-A7D2-BA1F5D9C64F5Q33399280-4B9DD2ED-1EC0-406B-8DC5-0C88D00851BBQ33402974-92E42586-39DA-4455-9A14-58C8B48F7318Q33403607-D27B9D76-02CA-4A71-AA58-EE45800821F0Q33407898-DEF02562-5B8F-4791-8722-F948D7E52A4BQ33410195-A20CEDB2-6B43-4667-94C7-F6DE1965D54BQ33411400-57F354C0-01BE-41DA-98EB-9D6F925C76F9Q33411402-2D2DB802-606F-4177-A889-A22460940167Q33414109-4E800538-D636-476C-99EC-A08884B0DC5BQ33419905-9DDD2722-1BA0-4D57-83F3-910605F3ADA6Q33422371-9CA3B249-33F3-4585-B946-DAC1D272E4B6Q33423135-5002A364-35FA-47DA-88D9-63F271F08C31Q34633739-DBBDF60D-57F3-4D1E-90D3-123E1C2C2C69Q34963775-9B5DF37B-AB22-4B49-BEDE-E081715C0294Q36283294-9EAA5C19-48F3-4B78-B120-3CBF62254A88Q37170492-FEBB2DC7-A421-4864-A057-F34028807203Q37417488-7EAE68D9-B652-4FBC-93FE-24F1A32162D9Q38123075-2CBF85D0-80D2-48AF-9DAB-25D95E6443D6Q38732762-41D631A5-5684-4FF5-A1CB-BB2A7CF736A5Q38903254-59798075-621A-4217-AD14-DD878D135F9DQ38991026-E5365A3A-B7B8-43F4-AEE5-9FAB685C3FA2Q39016179-5170A65A-9841-4F09-B580-CEBADCC3D55FQ39679330-6E3CD737-C894-4CEA-8995-213E2E3814FFQ40306147-D3019C49-6F6B-475B-AD4E-B8814F450278Q40474979-37EEFE21-783B-4646-B827-B948D60565F6Q41700443-B403FB93-6134-4BF4-8832-CD68F76C2FE4Q43537152-AF91B031-A4EA-4A81-9C12-4705DF36DE22Q44260998-DAEF5DCA-93DB-40F5-AC0A-A9FEC7BAADE9Q45858247-7C390DA1-4F90-45CB-82D6-FC47A6BD5BEBQ45888946-B24FED35-0871-4FEE-9A56-EC3F8BE87670Q46566817-3777313E-8BC1-4D41-9E42-10C1951399D3Q46955960-2D81D8A9-C78F-4895-B236-870091BFE879Q48146662-43B41ADB-6481-4EF0-9C19-19155233709CQ48324647-E8B6676F-20BB-4CD3-A28C-C429791B84B4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lubka T Roumenina
@nl
Lubka T Roumenina
@sl
Lubka T. Roumenina
@en
Lubka T. Roumenina
@es
type
label
Lubka T Roumenina
@nl
Lubka T Roumenina
@sl
Lubka T. Roumenina
@en
Lubka T. Roumenina
@es
altLabel
Lubka T. Roumenina
@en
prefLabel
Lubka T Roumenina
@nl
Lubka T Roumenina
@sl
Lubka T. Roumenina
@en
Lubka T. Roumenina
@es
P106
P1153
8841921600
P2798
P31
P496
0000-0002-9940-0324